An interventional study of Hemodialysis sessions in End Stage Renal Disease (ESRD), sponsored by Poitiers University Hospital. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.
Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 57th largest by enrollment of the 105 interventional ones that give a count, is one of 7 that started in 2022, is one of 55 with no phase, and was the 117th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
University of Avignon · Sites in France
Ages 20–79
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–17 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 26 · Phase 4 9
First in 1994; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 70 across the 105 interventional studies, 177 across the 40 observational. Of the 90 that completed or were terminated, 15 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 145 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 3 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Failure, Chronic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
| NCT06474169Centre Hospitalier Régional d'OrléansAssessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. | 2026-12 |
| NCT06595680Hospices Civils de LyonDevelopment of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins | 2027-01-22 |
| NCT06887075University Hospital, BordeauxSystemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation | 2027-02-15 |
| NCT05753930Hansa Biopharma ABImlifidase Prior to Kidney Transplant in Highly Sensitised Children | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 145 studies in Kidney Failure, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In patients on maintenance hemodialysis (HD), protein energy wasting (PEW) defined as loss of muscle mass and fuel reserves of the body is frequent and associated with severe morbidity and mortality. Several factors, including inflammation, oxidative stress, metabolic disorders, loss of nutrients, diabetes, retention of middle molecule uremic toxins and dialysis procedure contribute to PEW. It has been previously reported that intensive HD treatments such as short daily and nocturnal HD may improve nutritional parameters. Moreover, post-dilution Online hemodiafiltration (OL-HDF) may also improve PEW by preserving lean body mass evaluated by bioimpedance analysis (BIA) probably through decreased inflammation, stimulation of appetite and better removal of uremic toxins. The recently developed medium cut-off dialyzer (MCO) in HD has demonstrated efficient depuration of middle uremic toxins as compared to high flux HD (HF-HD), similar to that of OL-HDF. Both MCO-HD and OL-HDF may exert beneficial effects on PEW, since they increase removal of higher weight middle molecules, which mostly encompass proteins related to inflammation and PEW in the uremic milieu
In a previous randomized study, we found, that after 3 months, MCO-HD was associated with higher middle molecules removal and significant decrease in beta2-microglobulin, oxidized low-density lipoprotein, kappa and lambda free light chain pre-dialysis levels, without change in other inflammatory and oxidative stress biomarkers. In addition, compared to HF-HD, a modulation of inflammation has been demonstrated with MCO-HD in another randomized trial. After 3 months, MCO-HD was shown to downregulate the expression of the pro-inflammatory IL-6 and tumor necrosis factor (TNF) mRNA in peripheral leucocytes. Moreover, higher removal and decrease in TNF alpha level with concurrent reduced resistance to erythropoiesis stimulating agents (ESA) has been also reported with MCO-HD. However, the long-term effects of MCO-HD on inflammatory, uremic toxins and malnutrition biomarkers remain to be established.
To test the hypothesis that MCO-HD may positively affect body composition and nutritional status in HD patients we performed a 12-month single center retrospective pilot study. Compared to HF-HD, MCO-HD resulted in an improved variation rate of serum pre-dialysis creatinine level, lean tissue, skeletal muscle mass and index assessed by BIA, which are presumably good surrogate markers of PEW.
The aim of the present prospective, controlled randomized study is to evaluate the effect of MCO-HD on PEW, compared to standard HF-HD in chronic hemodialysis patients.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg)
Other: Hemodialysis sessions
Hemodialysis sessions using the Elisio 21H™ (Nipro Europe, Zaventen Belgium; surface area 2.1 m², ultrafiltration coefficient: 82 ml/h/mmHg)
Other: Hemodialysis sessions
Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
The Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study.
The difference between the lean tissue mass measured at 12 months and the lean tissue mass measured at baseline.
Time frame: 12 months
| Milestone | MCO-HD Group | HF-HD Group |
|---|---|---|
| Started | 32 | 32 |
| Completed | 24 | 23 |
| Not completed | 8 | 9 |
The difference between the lean tissue mass measured at 12 months and the lean tissue mass measured at baseline.
| kg | MCO-HD Group | HF-HD Group |
|---|---|---|
| The Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study. | 0.57 (-3.51 to 4.65) | 0.32 (-4.02 to 4.67) |
Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MCO-HD Group | 2/32 (6.3%) | 0/32 (0%) | 1/32 (3.1%) |
| HF-HD Group | 3/32 (9.4%) | 0/32 (0%) | 0/32 (0%) |
| Event | MCO-HD Group | HF-HD Group |
|---|---|---|
| hypotensive eventVascular disorders | 1/32 | 0/32 |
| Age, Continuous(years) | MCO-HD Group | HF-HD Group | Total |
|---|---|---|---|
| Median | 70.5 (65.5 to 74) | 70.0 (62.0 to 76.0) | 70.0 (64.0 to 75.0) |
| Sex: Female, Male(Participants) | MCO-HD Group | HF-HD Group | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 17 | 13 | 30 |
| Race and Ethnicity Not Collected(Participants) | MCO-HD Group | HF-HD Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| lean tissue mass at baseline(kg) | MCO-HD Group | HF-HD Group | Total |
|---|---|---|---|
| Mean | 44.7 ± 12.5 | 44.1 ± 11.6 | 44.4 ± 12.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in Mar 2025, 30 months.
Results were first posted in Oct 2026, 1 year 7 months after primary completion.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 30 months is above that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →